Overview of Chronic Hepatitis B Management

Overview

Journal Nurse Pract

Specialty Nursing

Date 2024 Dec 19

PMID 39696735

Authors

Angela Jun

Sherona Bau

John S Kim

Susanne J Phillips

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B remains a substantial global health challenge, impacting approximately 254 million people worldwide. A cure for this condition is yet to be discovered. Early identification and effective treatments coupled with vigilant monitoring can help alleviate associated morbidity and mortality due to potential complications such as liver cirrhosis and hepatocellular carcinoma.

References

Martin P, Nguyen M, Dieterich D, Lau D, Janssen H, Peters M . Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2021; 20(8):1766-1775. DOI: 10.1016/j.cgh.2021.07.036. View

Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, Murad M . AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2015; 63(1):261-83. PMC: 5987259. DOI: 10.1002/hep.28156. View

Kaholokula J, AuYoung M, Chau M, Sambamoorthi U, Carson S, Thao C . Unified in Our Diversity to Address Health Disparities Among Asian Americans, Native Hawaiians, and Pacific Islanders. Health Equity. 2022; 6(1):540-545. PMC: 9518805. DOI: 10.1089/heq.2022.0034. View

Yim H, Kim J, Park J, Yoon E, Park H, Kwon J . Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020; 26(4):411-429. PMC: 7641563. DOI: 10.3350/cmh.2020.0049. View

Veronese P, Dodi I, Esposito S, Indolfi G . Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol. 2021; 27(26):4182-4193. PMC: 8311536. DOI: 10.3748/wjg.v27.i26.4182. View

Cho J, Sohn W, Sinn D, Gwak G, Paik Y, Choi M . Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean J Intern Med. 2016; 32(4):636-646. PMC: 5511938. DOI: 10.3904/kjim.2016.096. View

Nelson N, Easterbrook P, McMahon B . Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clin Liver Dis. 2016; 20(4):607-628. PMC: 5582972. DOI: 10.1016/j.cld.2016.06.006. View

Corcorran M, Kim N . Chronic hepatitis B and HIV coinfection. Top Antivir Med. 2023; 31(1):14-22. PMC: 10089291. View

Conners E, Panagiotakopoulos L, Hofmeister M, Spradling P, Hagan L, Harris A . Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep. 2023; 72(1):1-25. PMC: 9997714. DOI: 10.15585/mmwr.rr7201a1. View

10.

Liu Y, Corsa A, Buti M, Cathcart A, Flaherty J, Miller M . No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2016; 24(1):68-74. DOI: 10.1111/jvh.12613. View

11.

Lee J, Cho Y, Lee D, Lee M, Yoo J, Choi W . Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014; 58(3):1730-7. PMC: 3957876. DOI: 10.1128/AAC.02483-13. View

12.

. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2):370-398. DOI: 10.1016/j.jhep.2017.03.021. View

13.

Seto W, Lo Y, Pawlotsky J, Yuen M . Chronic hepatitis B virus infection. Lancet. 2018; 392(10161):2313-2324. DOI: 10.1016/S0140-6736(18)31865-8. View

14.

Chan H, Fung S, Seto W, Chuang W, Chen C, Kim H . Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2017; 1(3):185-195. DOI: 10.1016/S2468-1253(16)30024-3. View

15.

Seeger C, Mason W . Molecular biology of hepatitis B virus infection. Virology. 2015; 479-480:672-86. PMC: 4424072. DOI: 10.1016/j.virol.2015.02.031. View

16.

Sachar Y, Brahmania M, Dhanasekaran R, Congly S . Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses. 2021; 13(7). PMC: 8310362. DOI: 10.3390/v13071318. View

17.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-1599. PMC: 5975958. DOI: 10.1002/hep.29800. View

18.

Bertoletti A, Naoumov N . Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol. 2003; 39(1):115-24. DOI: 10.1016/s0168-8278(03)00126-0. View

19.

Fletcher G, Eapen C, Abraham P . Hepatitis B genotyping: The utility for the clinicians. Indian J Gastroenterol. 2019; 39(4):315-320. DOI: 10.1007/s12664-019-00995-y. View

20.

Venkatakrishnan B, Zlotnick A . The Structural Biology of Hepatitis B Virus: Form and Function. Annu Rev Virol. 2016; 3(1):429-451. PMC: 5646271. DOI: 10.1146/annurev-virology-110615-042238. View